ACCC accuses Voltaren manufacturers of ‘misleading representations’ in marketing messages
The Australian Competition and Consumer Commission (ACCC) watchdog has initiated legal proceedings against GSK and Novartis alleging the drug companies made “false or misleading representations” in the marketing of its Voltaren Osteo Gel and Voltaren Emulgel pain relief products.
The ACCC is alleging Novartis and GSK encouraged consumers to buy its Osteo Gel product, which is offered at a premium price, instead of Emulgel despite the products containing the same ingredients.
The drug companies allegedly encouraged consumers to buy Osteo Gel because it is specifically formulated for treating osteoarthritis conditions.
